Quarterly ResultAug 5, 2026, 07:07 AM
Orthofix Q2 Net Sales $210.9M; Raises FY26 Guidance
AI Summary
Orthofix Medical Inc. reported its second quarter 2026 financial results, with net sales reaching $210.9 million, marking a 5% increase on a pro forma constant currency basis compared to the prior year. The company demonstrated continued operational progress, achieving double-digit constant currency growth in Global Spine Fixation and Global Limb Reconstruction. Following these results, Orthofix raised its full-year 2026 guidance for both net sales and adjusted EBITDA, reflecting confidence in its ongoing transformation and disciplined execution.
Key Highlights
- Second quarter 2026 reported net sales were $210.9 million, up 5% on a pro forma constant currency basis.
- Raised full-year 2026 net sales guidance to $845 million-$855 million, up $7 million at both ends.
- Increased full-year 2026 non-GAAP adjusted EBITDA guidance to $95 million-$98 million, up $5 million at both ends.
- Second quarter 2026 non-GAAP adjusted EBITDA was $20.1 million, or 9.6% of pro forma net sales.
- Reported net loss for Q2 2026 was $(15.8) million, or $(0.39) per share.
- Global Limb Reconstruction achieved 11.0% constant currency growth in Q2 2026.
- Therapeutic Solutions delivered 2.5% year-over-year net sales growth in Q2 2026.
- Cash, cash equivalents, and restricted cash totaled $104.4 million as of June 30, 2026.
Price Impact
More from OFIX